Superstring Capital Management L.P. 13F annual report
Superstring Capital Management L.P. is an investment fund managing more than $151 billion ran by George Song. There are currently 37 companies in Mr. Song’s portfolio. The largest investments include Cytokinetics Inc and Nkarta, together worth $32.4 billion.
$151 billion Assets Under Management (AUM)
As of 8th May 2024, Superstring Capital Management L.P.’s top holding is 278,915 shares of Cytokinetics Inc currently worth over $19.6 billion and making up 12.9% of the portfolio value.
Relative to the number of outstanding shares of Cytokinetics Inc, Superstring Capital Management L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 1,189,193 shares of Nkarta worth $12.9 billion, whose value grew 221.8% in the past six months.
The third-largest holding is 89bio Inc worth $11 billion and the next is BridgeBio Pharma Inc worth $10.9 billion, with 353,507 shares owned.
Currently, Superstring Capital Management L.P.'s portfolio is worth at least $151 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Superstring Capital Management L.P.
The Superstring Capital Management L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, George Song serves as the COO/CFO at Superstring Capital Management L.P..
Recent trades
In the most recent 13F filing, Superstring Capital Management L.P. revealed that it had opened a new position in
Cabaletta Bio Inc and bought 290,797 shares worth $4.96 billion.
This means they effectively own approximately 0.1% of the company.
Cabaletta Bio Inc makes up
4.0%
of the fund's Health Care sector allocation and has decreased its share price by 2.2% in the past year.
The investment fund also strengthened its position in Cytokinetics Inc by buying
101,312 additional shares.
This makes their stake in Cytokinetics Inc total 278,915 shares worth $19.6 billion.
Cytokinetics Inc soared 52.4% in the past year.
On the other hand, there are companies that Superstring Capital Management L.P. is getting rid of from its portfolio.
Superstring Capital Management L.P. closed its position in Immunogen on 15th May 2024.
It sold the previously owned 598,072 shares for $17.7 billion.
George Song also disclosed a decreased stake in 89bio Inc by approximately 0.1%.
This leaves the value of the investment at $11 billion and 941,287 shares.
One of the smallest hedge funds
The two most similar investment funds to Superstring Capital Management L.P. are Baron and Potrero Capital Research. They manage $151 billion and $151 billion respectively.
George Song investment strategy
Superstring Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 82.3% of
the total portfolio value.
The fund focuses on investments in the United States as
62.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
11% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.13 billion.
The complete list of Superstring Capital Management L.P. trades based on 13F SEC filings
These positions were updated on May 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Cytokinetics Inc |
57.04%
278,915
|
$19,554,730,000 | 12.93% |
| Immunogen, Inc. |
Closed
598,072
|
$17,732,835,000 | |
| Nkarta, Inc. |
242.33%
1,189,193
|
$12,855,176,000 | 8.50% |
| 89bio Inc |
7.85%
941,287
|
$10,956,580,000 | 7.24% |
| BridgeBio Pharma Inc |
71.33%
353,507
|
$10,930,436,000 | 7.23% |
| Savara Inc |
153.62%
2,065,144
|
$10,284,417,000 | 6.80% |
| IDEAYA Biosciences, Inc. |
13.62%
217,070
|
$9,525,031,000 | 6.30% |
| Protagonist Therapeutics Inc |
Closed
379,143
|
$8,693,749,000 | |
| Immunovant Inc |
Closed
203,592
|
$8,577,331,000 | |
| Fate Therapeutics Inc |
8.57%
920,476
|
$6,756,294,000 | 4.47% |
| Day One Biopharmaceuticals I |
7.89%
349,679
|
$5,776,697,000 | 3.82% |
| Roivant Sciences Ltd |
62.81%
531,019
|
$5,596,940,000 | 3.70% |
| Ionis Pharmaceuticals Inc |
36.24%
120,896
|
$5,240,842,000 | 3.47% |
| Marinus Pharmaceuticals Inc |
22.30%
565,550
|
$5,112,572,000 | 3.38% |
| Cabaletta Bio Inc |
Opened
290,797
|
$4,960,997,000 | 3.28% |
| UroGen Pharma Ltd |
12.86%
288,267
|
$4,324,005,000 | 2.86% |
| Verona Pharma Plc |
109.11%
259,383
|
$4,173,472,000 | 2.76% |
| Neurocrine Biosciences, Inc. |
Closed
29,346
|
$3,866,629,000 | |
| Lantheus Holdings Inc |
Closed
54,896
|
$3,403,552,000 | |
| Aerovate Therapeutics Inc |
Opened
110,264
|
$3,260,506,000 | 2.16% |
| Apogee Therapeutics Inc |
Opened
44,868
|
$2,981,479,000 | 1.97% |
| Axsome Therapeutics Inc |
126.26%
36,607
|
$2,921,239,000 | 1.93% |
| Dyne Therapeutics, Inc. |
Opened
99,822
|
$2,833,947,000 | 1.87% |
| Acelyrin Inc |
Closed
356,924
|
$2,662,653,000 | |
| Praxis Precision Medicines I |
Opened
40,119
|
$2,448,061,000 | 1.62% |
| Allogene Therapeutics Inc |
134.68%
521,249
|
$2,329,983,000 | 1.54% |
| Keros Therapeutics, Inc. |
54.68%
33,828
|
$2,239,413,000 | 1.48% |
| Pyxis Oncology Inc |
Opened
493,759
|
$2,103,414,000 | 1.39% |
| Krystal Biotech Inc |
Closed
16,086
|
$1,995,629,000 | |
| Quanterix Corp |
Closed
71,760
|
$1,961,918,000 | |
| Ascendis Pharma A/S |
Opened
12,754
|
$1,928,022,000 | 1.27% |
| Pepgen Inc |
Opened
114,385
|
$1,681,460,000 | 1.11% |
| Tourmaline Bio Inc |
Opened
69,972
|
$1,602,359,000 | 1.06% |
| Allakos Inc |
Opened
1,233,739
|
$1,554,512,000 | 1.03% |
| CytomX Therapeutics Inc |
Opened
679,403
|
$1,481,099,000 | 0.98% |
| Annexon Inc |
Opened
155,728
|
$1,116,569,000 | 0.74% |
| Avidity Biosciences, Inc. |
Opened
37,031
|
$945,031,000 | 0.62% |
| Lyra Therapeutics, Inc. |
Opened
145,284
|
$903,667,000 | 0.60% |
| Inozyme Pharma, Inc. |
9.04%
112,739
|
$863,581,000 | 0.57% |
| Immatics N.v |
Closed
79,213
|
$834,113,000 | |
| Aurinia Pharmaceuticals Inc |
Opened
98,691
|
$494,443,000 | 0.33% |
| Fusion Pharmaceuticals Inc. |
Closed
45,801
|
$440,148,000 | |
| KalVista Pharmaceuticals Inc |
Opened
32,025
|
$379,817,000 | 0.25% |
| Alpine Immune Sciences Inc |
Opened
9,038
|
$358,267,000 | 0.24% |
| Spruce Biosciences, Inc. |
270.52%
440,225
|
$345,973,000 | 0.23% |
| Ys Biopharma Co Ltd |
No change
307,920
|
$215,544,000 | 0.14% |
| So-Young International Inc. |
77.04%
182,742
|
$199,189,000 | 0.13% |
| No transactions found | |||
| Showing first 500 out of 47 holdings | |||
Hedge funds similar to Superstring Capital Management L.P.
- Lifepro Asset Management
- Column
- Walker Asset Management
- Cape Ann Savings Bank
- Element Capital Management
- Potrero Capital Research
- Baron
- Lynx1 Capital Management L.P.
- Insight Wealth Partners
- Brogan Financial, Inc
- Rbc Trust (international)
- Ascension Capital Advisors
- Garland Capital Management Inc
- Kercheville Advisors